200,000+ products from a single source!
sales@angenechem.com
Home > Imidazoles > 13551-92-3
13551-92-3 | 3-(2-Nitro-1H-imidazol-1-yl)propane-1,2-diol
CAS No: 13551-92-3 Catalog No: AG006YUX MDL No:MFCD00866412
Product Description
Catalog Number:
AG006YUX
Chemical Name:
3-(2-Nitro-1H-imidazol-1-yl)propane-1,2-diol
CAS Number:
13551-92-3
Molecular Formula:
C6H9N3O4
Molecular Weight:
187.1534
MDL Number:
MFCD00866412
IUPAC Name:
3-(2-nitroimidazol-1-yl)propane-1,2-diol
InChI:
InChI=1S/C6H9N3O4/c10-4-5(11)3-8-2-1-7-6(8)9(12)13/h1-2,5,10-11H,3-4H2
InChI Key:
NUGLIYXAARVRPQ-UHFFFAOYSA-N
SMILES:
[O-][N+](=O)c1nccn1CC(CO)O
EC Number:
236-932-1
NSC Number:
261036
Properties
Complexity:
183
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
0
Exact Mass:
187.059g/mol
Formal Charge:
0
Heavy Atom Count:
13
Hydrogen Bond Acceptor Count:
5
Hydrogen Bond Donor Count:
2
Isotope Atom Count:
0
Molecular Weight:
187.155g/mol
Monoisotopic Mass:
187.059g/mol
Rotatable Bond Count:
3
Topological Polar Surface Area:
104A^2
Undefined Atom Stereocenter Count:
1
Undefined Bond Stereocenter Count:
0
XLogP3:
-1
Literature
| Title | Journal |
|---|---|
| Microsphere-based protease assays and screening application for lethal factor and factor Xa. | Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501 |
| The neurotoxicity of radiosensitizing drugs: a biochemical assessment of desmethylmisonidazole (DMM) in the rat. | Toxicology 19850101 |
| Oncogenic transformation systems involving mammalian cells in vitro to determine the relative risks of different treatment modalities. | Strahlentherapie 19841201 |
| The role of microsomal enzyme inducers in the reduction of misonidazole neurotoxicity. | The British journal of radiology 19831101 |
| Activation of misonidazole by rat liver microsomes and purified NADPH-cytochrome c reductase. | Biochemical pharmacology 19820215 |
| Structure-function dependence and allopurinol inhibition of radiosensitizer/nitroreductase interaction: approaches to improving therapeutic ratios. | Cancer clinical trials 19800101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.